TheraRadar
Data updated: May 26, 2026

XURIDEN (uridine triacetate)

Rare Disease Approved 2015-09-04

Xuriden treats hereditary orotic aciduria in both adult and pediatric patients. This medication helps patients who have a genetic defect that prevents them from synthesizing enough uridine nucleotides on their own. It serves as a replacement therapy to ensure there is an adequate supply of uridine in the body's systemic circulation.

Source: FDA Label • BTG INTL

How XURIDEN Works

This medication works by delivering an acetylated form of uridine that the body converts into active uridine after oral administration. Once inside the body, enzymes called nonspecific esterases remove the acetyl groups, releasing uridine into the bloodstream. This process provides the necessary building blocks for patients who cannot produce sufficient quantities of uridine due to their genetic condition.

2
Indications
--
Phase 3 Trials
1
Priority Reviews
10
Years on Market

Details

Status
Prescription
First Approved
2015-09-04
Routes
ORAL
Dosage Forms
GRANULE

Companies

Active Ingredient: URIDINE TRIACETATE

XURIDEN Approval History

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
2 FDA actions from 2015 to 2019 · 1 indication expansions
Dec 2019 SUPPL
Efficacy
Sep 2015 ORIGINAL Priority
New Drug · Type 1 - New Molecular Entity

What XURIDEN Treats

1 indications

XURIDEN is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hereditary Orotic Aciduria
Source: FDA Label
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT02110147 results posted 401.13.001 Ph 3 completed Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

XURIDEN FDA Label Details

Indications & Usage

FDA Label (PDF)

XURIDEN is indicated for the treatment of Hereditary Orotic Aciduria.

Track XURIDEN with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.